Wedbush Securities Reiterates Neutral Rating, Raises Price Target On Boston Scientific On 4Q Recap

In a report published Thursday, Wedbush Securities analyst Tao Levy reiterated a Neutral rating on Boston Scientific Corporation BSX, and raised the price target from $16.00 to $17.00. In the report, Wedbush Securities noted, "BSX reported a generally in-line quarter, led by strength from its Interventional Cardiology, CRM, and Urology/Women's Health businesses. Overall, we are encouraged that the company's new product launches are gaining traction, and we have a favorable opinion of its pipeline. However, we believe BSX's share price fairly reflects its risk/reward outlook." Boston Scientific closed on Wednesday at $14.96.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetAnalyst RatingsTao LevyWedbush Securities
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!